Back to Home PageWelcome Guest! Register | Login | Home | Contact Us | Site Map | Advertise | FAQ | Search
Canadian Desi
    Charcha


        
  Canada Immigration Forum > About Canada > Life > COVID-19 Related News
Last Post | Newest Post
 
< [ 1 ] [ 2 ] [ 3 ] >

COVID-19 Related News




Hello Everyone,

I got suggestions from several members that we should provide information regarding COVID-19. While I can't provide the live tracker as it will require someone to constantly keep it updating, I also believe that we all have multiple sources to get that information.

What we can do is post here some useful links and tips for prevention, and survival.

Being desi means our main source of grocery supplies is from Indian Grocery Stores and with limited international connectivity many of our items are in short supply. If we can provide help in locating sources with availability it will be helpful.

Anything else that can help members is appreciated.

-----------------------------------------------------------------
A Proud Indian Canadian

 
Last edited by: Garvo Gujarati on 25-03-20 17:03:22
Garvo Gujarati
Member of Administrators
Admin
Member since: Nov 01
Posts: 3087
Location:

Post ID: 239036 25-03-20 17:00:17
Report Abuse
Garvo GujaratiMember of Administrators
Admin
Member since: Nov 01




Posts: 3087
Location:




Myself and family are doing just fine. Include my extended friend circle and relatives across north America. Hope everyone is doing great.

-----------------------------------------------------------------
A Proud Indian Canadian

 
Post ID: 239037 25-03-20 17:02:22
Report Abuse
Full House
Senior Desi
Member since: Oct 12




Posts: 2642
Location:



This website has permitted to post to everyone who partakes and shares with one another. I have also visited people who were in hospitals TWO WEEKS ago and knowing the hazards, I kept myself secluded and away from 'cilivisation' just in case I became a carrier of 'things'. Those two weeks are over and now I sleep peacefully knowing I am not a carrier of any transmittable diseases. And if I did, then, I have built immunity to it. That is good news.

Every local Hospital has opened up a Virus Wing and the Government is paying a handsome amount to man it and maintain it too. That is news. How good the services are we will know once it gets crammed up and please remember that you may have to say good-bye to those in the ward over a hand-held device. I see this over the TV broadcasts in ITALY. It is a very sad GOOD-BYE.

This virus was discovered or detected by the US ARMY and there are five grades of them. More on it when you google. This has stopped mingling of people and it will continue to be so till it is eradicated. Even after the abatement most people will avoid parties and other crowded events.

Our Economy has gone down the drain and our markets have killed all our financial strength and our ability to spend.

Grocery shelves are bare. In some places they are only allowing a few at a time to shop and not crowd their places.

The bargain that I find that the price for a Liter of gas has hit the rock bottom due to the fights between the CRUDE suppliers. I have picked up a regular at 63 Cents/l and a few have done the same at 61c/l. Please remember in about TWO weeks the Markets will get stabilized and for the LT. investors it will be time to get in and a year from now might regain their financial health.

What ever you do, please keep away from the public till it all blows over. Keep Good Health and Enjoy Life. (KGH&EL)

FH.




 
Post ID: 239038 25-03-20 18:12:31
Report Abuse
sudesingh
Senior Desi
Member since: Jul 04




Posts: 2081
Location: Toronto


If anyone is looking for atta, as-off 26-Mar-2020 @ 6:00 pm, Divya Sharbati Atta (by Gelda foods) is available at Food Basics, on Lawrence Ave E, bet. Warden Ave & Birchmount Ave, Scarborough. Cost is $10.99. It may not be the best price, but considering the circumstances, it's not a bad price.

Costco Business Centre, 50 Thermos road, Scarborough, had a few varieties of basmati rice both white and brown, priced approx. $8 to $10 / 10lbs. They also have Royal 20 lb for $20 and Duniya 40lb for $32.


-----------------------------------------------------------------
SS
Reiki Grand Master

 
Post ID: 239039 26-03-20 20:45:17
Report Abuse
Full House
Senior Desi
Member since: Oct 12




Posts: 2642
Location:


Here is a great Grocer and a trip will be well worth it.

https://www.asianfoodcentre.com/flyer/flyer.pdf

While you are there please look for ADM Atta. If you can use it in THREE months, then, you can live free in CANADA.

FH.

Food Basics carries Saporito Canola Oil for $3.88. Great product.

EDIT: The latest flyers are available inside the stores.
https://flyers.smartcanucks.ca/canada/asian-food-centre-flyer-december-18-to-january-5


 
Last edited by: Full House on 17-04-20 19:50:58
Post ID: 239040 27-03-20 05:43:21
Report Abuse
Full House
Senior Desi
Member since: Oct 12




Posts: 2642
Location:


TEST for COVID -19: A kit Manufactured by ABBOTT Labs of India seems to be one of the BEST one on the market. Please read and enjoy.

https://www.bloomberg.com/news/articles/2020-03-27/abbott-launches-5-minute-covid-19-test-for-use-almost-anywhere


Good News.

FH.

EDIT: W.H.O.
https://www.youtube.com/watch?v=1APwq1df6Mw

Canada : https://www.youtube.com/watch?v=5DGwOJXSxqg

INDIA.: EDIT.: https://www.worldometers.info/coronavirus/country/india/


 
Last edited by: Full House on 13-04-20 17:32:54
Post ID: 239043 28-03-20 04:01:37
Report Abuse
Full House
Senior Desi
Member since: Oct 12




Posts: 2642
Location:


---



HubJohns Hopkins University

WHAT WILL IT TAKE TO DEVELOP A VACCINE FOR COVID-19? Johns Hopkins global health expert Ruth Karron discusses the work currently taking place at laboratories around the country to develop a vaccine for COVID-19
Published March 26. 2020.

This week, the National Institutes of Health announced that Kaiser Permanente has begun the first clinical trial of a COVID-19 vaccine, called mRNA-1273. Scientists estimate that it will take at least one year to make a COVID-19 vaccine available to the general public.

To understand the steps required to develop, test, and produce a COVID-19 vaccine ready for usage, Sarah LaFave, a PhD candidate at the Johns Hopkins School of Nursing, spoke with Ruth Karron, a professor in the Department of International Health at the Bloomberg School of Public Health. Karron is the founding director of the Johns Hopkins Vaccine Initiative and director of the Center for Immunization Research. Their conversation has been edited for length and clarity.

LaFave: Who is working on developing a COVID vaccine?
Karron: There are a number of groups working on vaccines—in academia, in biotech, in pharma. The developers are using new technologies which will allow for rapid development, but we also aren't sure yet how those new technologies will work. That's why it's important that we have multiple groups working on developing multiple vaccines.

Johns Hopkins responds to COVID-19 : Coverage of how the COVID-19 pandemic is affecting operations at JHU and how Hopkins experts and scientists are responding to the outbreak

How far along are scientists toward having a COVID vaccine?
The first COVID vaccine was developed just four weeks after the first genetic sequence was available from China. The reason that was possible was in part because of investment by the Coalition for Epidemic Preparedness and Innovation. CEPI is a global partnership set up three years ago, specifically with a mission "to stimulate and accelerate the development of vaccines against emerging infectious diseases and enable access to these vaccines for people during outbreaks." One of the things they have focused on is preparing for "Disease X," meaning some disease that would exist in the future which we didn't yet know about and for which we didn't yet have a vaccine. CEPI was founded to support the development of technology platforms that—no matter what the pathogen—could be used for rapid vaccine development. These technologies allow you to go from genetic sequence to vaccine without having to isolate the germ. COVID-19 is Disease X.

We're hearing about both a COVID vaccine and COVID antivirals. What's the difference and when do you think we will see a COVID vaccine or antiviral available to the general public?

That's really difficult to project. We will likely know if we have a vaccine within six to nine months but then the challenge will be to scale up production. Developing and testing a vaccine is different from developing, say, an antiviral which you would use to treat someone who has an infection. If you are giving an antiviral in a treatment trial for someone with COVID, you reach the endpoint very quickly—you look at the outcome for that patient immediately. But with a vaccine, you don't reach the endpoint immediately because you have to observe immune response over time, and for an efficacy study, have enough people naturally exposed to the virus to determine whether the vaccine prevents disease. That's why you will likely hear about results from COVID treatment studies before you will hear about results from COVID vaccine studies. There are also data coming out that suggest that different strains of COVID might exist. We don't yet know the biologic relevance of that, but it will be important to find out whether the vaccines and the antivirals are equally effective against all strains.

What are the key steps for bringing a vaccine to market?
First there's the creation of the vaccine itself. Often, the vaccine is next evaluated in animals, depending on the vaccine and the particular disease. Then, under oversight from regulators (the Food and Drug Administration in the U.S., and other regulatory bodies in other countries), institutional review boards (IRBs), and Data Safety and Monitoring Boards (DSMBs), the vaccine moves through phases of clinical testing, typically first in small numbers of healthy younger adults, and then in larger groups and broader age ranges, often including people with underlying conditions. The CDC has a useful brief guide to the phases of vaccine testing online.

"THERE ARE ASPECTS OF THE TRIALS THAT JUST CAN'T BE RUSHED. IT TAKES TIME TO DEVELOP AN IMMUNE RESPONSE TO THE VACCINE, AND IT ALSO TAKES TIME TO EVALUATE THE SAFETY OF THESE VACCINES."

Once a vaccine is shown to be safe and effective, bringing a vaccine to market is a complex effort that requires investment in manufacturing and distribution. In the coming months, we and others around the world will need to be thinking and acting to ensure that adequate investments are made, and will need to continue to collect and review data to determine who should be vaccinated, and when. You'll probably remember that with the 2009 flu pandemic, we didn't have enough vaccine available for everyone at once, so we prioritized vaccination based on risk. And of course this is a global disease—so we need to be thinking about issues of global equity and justice as we consider vaccine supply.

Is there a fast-track that can be taken during situations like the one we're in now?
We have fast-tracked vaccine development—getting from pathogen sequence to vaccine products available for clinical trials in a matter of weeks is a truly remarkable accomplishment. However, there are aspects of the trials that just can't be rushed. It takes time to develop an immune response to the vaccine, and it also takes time to evaluate the safety of these vaccines.

With that said, in an emergency situation, some stages of vaccine testing can be streamlined. How quickly you progress through the stages of vaccine evaluation will be influenced by the urgency of the problem. In the context of a pandemic, I know that we will move forward as safely and quickly as possible.

What is the most important thing for the general public to know about COVID vaccine development?
Vaccines are critical to halt the coronavirus pandemic—but they are not an overnight solution.

I also think it's important for people to understand that without investment in vaccine epidemic preparedness and technology, the rapid development of vaccines using novel platforms that is now underway wouldn't have been possible.

In 2015, Stanley Plotkin, Adel Mahmoud and Jeremy Farrar published a landmark article in the New England Journal of Medicine in which they called for the establishment of an organization like CEPI to support rapid vaccine development. Many of the vaccines that are in development for COVID-19 were made possible because researchers had seed funding for technologies that make rapid vaccine development possible. That funding came from CEPI before we ever knew COVID-19 would exist.

xxxx

FH.
https://hub.jhu.edu/2020/03/26/covid-19-vaccine-development-ruth-karron/

https://main.mohfw.gov.in/

SINCE WE DO NOT KNOW WHO HAS IT, IT IS BETTER TO KEEP A DISTANCE FROM EACH OTHER AND PLAY IT SAFE TILL IT ALL BLOWS OVER AND WE FEEL CONFIDENT TO MIX WITH FRIENDS AND SOCIALIZE. IT JUMPS FROM OUR SPEAKING AND BREATHING. SO, WEAR A MASK TO AVOID THE SPRAY AND SPREADING.

IN-SHORT STAY INDOORS AND STAY ALOOF. (IT COULD BE A THREE WEEK FURLOUGH.)

EDIT: 3rd APRIL 2020 W.H.O.

SUBJECT IN FOCUS: The routes of transmission from COVID-19 patients
As the COVID-19 outbreak continues to evolve, we are learning more about this new virus every day. Here we summarize what has been reported about the transmission of the COVID-19 virus, and provide a brief overview of available evidence on transmission from symptomatic, pre-symptomatic and asymptomatic people infected with COVID-19.

Symptomatic transmission By way of definition, a-symptomatic COVID-19 case is a case wherein one has developed signs and symptoms compatible with COVID-19 virus infection. Needs a Testing for the COVID 19 attack.

Symptomatic transmission refers to transmission from a person while they are experiencing symptoms. Data from published epidemiology and virologic studies provide evidence that COVID-19 is primarily transmitted from symptomatic people to others 'who are in close contact through respiratory droplets', by direct contact with infected persons, or by contact with contaminated objects and surfaces.

1-7 This is supported by detailed experiences shared by technical partners via WHO global expert networks, and reports and presentations by Ministries of Health. Data from clinical and virologic studies that have been collected repeated biological samples from confirmed patients provide evidence that shedding of the COVID-19 virus is highest in the upper respiratory tract (nose and throat) early in the course of the disease.

8-10 That is, within the first 3 days from onset of symptoms.

10-11 Preliminary data suggests that people may be more contagious around the time of symptom onset as compared to later on in the disease. Pre-symptomatic transmission.

The incubation period for COVID-19, which is the time between exposure to the virus (becoming infected) and symptom onset, is on average 5-6 days, this however can be up to 14 days. During this period, also known as the “pre-symptomatic” period, some infected persons can be contagious. (Due to poor health) Therefore, transmission from a pre-symptomatic case can occur before symptom onset. In a small number of case reports and studies, a pre-symptomatic transmission has been documented through contact tracing efforts and enhanced investigation of clusters of confirmed cases. 12-17 This is supported by data suggesting that some people can test positive for COVID-19 from 1-3 days before they develop symptoms.

6,16 Thus, it is possible that people infected with COVID-19 could transmit the virus before any significant symptoms develop. Hence, it is important to recognize that pre-symptomatic transmission still requires the virus to be spread via infectious droplets or through touching contaminated surfaces.

Asymptomatic transmission: An asymptomatic laboratory-confirmed case is a person infected with COVID-19 who does not develop symptoms. Asymptomatic transmission refers to the transmission of the virus from a person, who does not develop symptoms. There are few reports of laboratory-confirmed cases who are truly asymptomatic, and to date, there has been no documented asymptomatic transmission. This does not exclude the possibility that it may occur. Asymptomatic cases have been reported as part of contact tracing efforts in some countries. WHO regularly monitors all emerging evidence about this critical topic and will provide an update as more information becomes available.

F.H. Edited 3 Ap/20.


 
Last edited by: Full House on 03-04-20 02:58:29
Post ID: 239046 30-03-20 02:30:31
Report Abuse
Garvo GujaratiMember of Administrators
Admin
Member since: Nov 01




Posts: 3087
Location:



The health officials are in the fire-fighting mode - some in treatments, some in searching for vaccine. This might not be a time to analyze but someone really need to think what makes the Asian Countries more robust against COVID-19 as compared to western countries. The South Africa and most of the South American Countries are doing very well.

Food habits? Spices in the food? Relying more on hot drinks and not added ice?
Immunity developed over the time by having frequent malaria, flu etc.?
Immunity just because of pure polution in the air and water and food?

-----------------------------------------------------------------
A Proud Indian Canadian

 
Post ID: 239047 31-03-20 11:32:05
Report Abuse
Full House
Senior Desi
Member since: Oct 12




Posts: 2642
Location:



--
COVID 19, TORONTO. COVID-19: Status of Cases in Toronto

Last updated: April 8, 2020 at 4:00 p.m.

If you think you have COVID-19 symptoms or have been in close contact with someone who has it, find out if you should visit an assessment centre and where to go.

This daily summary was extracted from the Integrated Public Health Information System at 12:30 p.m. on April 8, 2020. The numbers may differ from other sources, as data are extracted at different times.

Please read on. (Click on the link below)

FH.

https://www.toronto.ca/home/covid-19/media-room/covid-19-status-of-cases-in-toronto/


 
Post ID: 239060 09-04-20 11:51:03
Report Abuse
Full House
Senior Desi
Member since: Oct 12




Posts: 2642
Location:



xx

Deadly coronavirus comes in three variants, researchers find Types A, B and C are all derived from the pathogen first found in bats but have evolved in different ways, according to a report by British and German geneticists. Findings show that the virus has become well adapted to human transmission and mutates as it spreads, Chinese epidemiologist says.

Covid-19 may attack human immune system like HIV, doctors fear. The study suggests coronavirus can infect T cells.

Nature magazine said that continuing to associate this virus with a specific place (Location) is irresponsible and needs to stop.

Animals hunted, traded and homeless host twice as many viruses that infect us

The spillover of viruses from animals to humans is a direct result of our actions involving wildlife and their habitat, according to the lead author of a new study.

In pandemic-gripped Washington, rhetoric rises but anti-China bills stall

Why Chinese diplomats are spoiling for a fight. Global race for virus vaccine heats up as China seeks volunteers for trial.

CanSino is recruiting healthy volunteers for a clinical trial of its vaccine candidate.

Bug in the system: why there’s no quick fix for a Covid-19 vaccine

The authors of the reports attack said an attack on China’s global trade would undermine its economy and threaten its stability.

The world is under attack from three variants of the deadly coronavirus, according to new research. Photo: EPA-EFEThe world is under attack from three variants of the deadly coronavirus, according to new research. Geneticists from Britain and Germany have mapped the evolutionary path of the coronavirus that causes Covid-19 and determined there are currently three versions of it spreading around the world. The discovery of how the variants were formed and then spread could help scientists to identify its source and explain why it is so contagious. The researchers analysed the first 160 complete viral genomes sequenced from human patients between December 24 and March 4, then reconstructed the early evolutionary pathway of Covid-19 in humans through its mutations.
“There are too many rapid mutations to neatly trace a Covid-19 family tree. We used a mathematical network algorithm to visualise all the plausible trees simultaneously,” said Peter Forster, a geneticist at University of Cambridge and lead author of the study.

“These techniques are mostly known for mapping the movements of prehistoric human populations through DNA. We think this is one of the first times they have been used to trace the infection routes of a coronavirus like Covid-19,” he said in a report about the study on the university’s website.

The team labelled the three variants A, B and C.

Type A was closest to the coronavirus discovered in bats and although found in Wuhan – the central China city that was the epicentre of the initial outbreak – was not the primary type there, they said.

Type A was also found in Americans who had lived in Wuhan, and in other patients diagnosed in the United States and Australia.

The most common variant found in Wuhan was type B, the study said, though this appeared not to have travelled much beyond East Asia before mutating, which the researchers said was probably due to some form of resistance to it outside that region. Coronavirus could target immune system by killing protective cells.

Finally, type C was the variant found most often in Europe based on cases in France, Italy, Sweden and England. It had not been detected in any patients in mainland China, though had been found in samples from Singapore, Hong Kong and South Korea, the study said.

The researchers concluded that variant A was the root of the outbreak as it was most closely related to the virus found in bats and pangolins.
Type B was derived from A, separated by two mutations, while type C was the “daughter” of variant B. “The Wuhan B-type virus could be immunologically or environmentally adapted to a large section of the East Asian population,” Forster said.
“It may need to mutate to overcome resistance outside East Asia. We seem to see a slower mutation rate in East Asia than elsewhere, in this initial phase.”

The research also documented how people’s movements had helped the spread of the virus.
For example, the study suggested that one of the earliest introductions of the virus to Italy – found in a Mexican traveller who was diagnosed on February 28 – came via the first documented German infection – a person who worked for a company in Munich – on January 27. The German contracted the infection from a Chinese colleague in Shanghai, who had recently been visited by her parents from Wuhan.

The researchers documented 10 mutations in the viral journey from Wuhan to Mexico.
“Because we have reconstructed the "family tree" (the evolutionary history) of the human virus, we can use this tree to trace infection routes from one human to the next, and thus have a statistical tool to suppress future infection when the virus tries to return,” Forster said.

He added that researchers can better determine when the outbreak started with the data. “I hope this improved knowledge of the origin and spread will enable more precise computer simulations to predict which measures will be most effective,” he said.

Lu Jiahai, an epidemiologist at Sun Yat-sen University Guangzhou, the capital of Guangdong, said the study had provided a preliminary analysis of genomics and molecular variation. “The virus mutates during spreading and has become more adapted to transmission among humans in different populations from different countries,” he said.

But as the variants were related to each other, tracking mutations within different groups could help to determine the origin of the virus, he said. “This research indicates that the spread of the virus is increasingly adapted to different populations and therefore the pandemic needs to be taken seriously,” Lu said.

“People need to pay more attention to prevention and control … the virus may coexist with humans for a long time.”

Enjoy reading it.

FH.

https://www.scmp.com/news/china/science/article/3079491/deadly-coronavirus-comes-three-variants-researchers-find



 
Post ID: 239079 14-04-20 02:13:02
Report Abuse
Contributors:
Full House(17)  Garvo Gujarati(3)  llzz101(1)  sudesingh(1)  
< [ 1 ] [ 2 ] [ 3 ] >
 
Show Printable version
Send this page to a friend
Add to favorites
 


 
Web
CanadianDesi
Please Contribute!
Write an Article
Send Community News
Create Photo and Video Albums
Submit Good Pictures
List Useful Websites
Post Jobs
Submit Events
List for FREE!
Businesses
Classifieds
Social Organizations
Religious Places
Employment Agencies
Email Page
Your Email
Friend\'s Email

Advertise Contact Us Privacy Policy and Terms of Usage FAQ
Canadian Desi
© 2001 Marg eSolutions


Site designed, developed and maintained by Marg eSolutions Inc.